Reteplase News
Reteplase currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Reteplase with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of...
- Evidence level: L5
- Predicted indications (20):
- myocardial infarction (99.9%)
- coronary thrombosis (99.9%)
- posteroinferior myocardial infarction (99.9%)
- posterolateral myocardial infarction (99.9%)
- septal myocardial infarction (99.9%)
- congenital coronary artery anomaly (99.8%)
- hemoglobinopathy (99.7%)
- coronary stenosis (99.6%)
- myocardial infarction (disease) (99.6%)
- heparin cofactor 2 deficiency (99.5%)
- partial deletion of the short arm of chromosome 16 (99.3%)
- beta-thalassemia with other manifestations (99.3%)
- antithrombin deficiency type 2 (99.2%)
- hemolytic anemia due to glucophosphate isomerase deficiency (99.2%)
- factor 5 excess with spontaneous thrombosis (99.2%)
- pyropoikilocytosis, hereditary (99.2%)
- pyruvate kinase deficiency of red cells (99.1%)
- thrombophilia (99.1%)
- pulmonary embolism (disease) (98.1%)
- primary release disorder of platelets (95.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.